LONA
NASDAQLeonaBio Inc.
News25/Ratings3
Price$8.80+3.23 (+58.08%)
2026-03-052026-06-08
News · 26 weeks57-80%
2025-12-142026-06-07
Mix4390d
- Insider18(42%)
- SEC Filings16(37%)
- Other6(14%)
- Leadership2(5%)
- Analyst1(2%)
Latest news
25 items- PRLeonaBio Presents on ATH-1105 at 5th Annual ALS Drug Development SummitBOTHELL, Wash., June 04, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ:LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced that Javier San Martin, MD, Chief Medical Officer of LeonaBio, delivered a presentation at the 5th Annual ALS Drug Development Summit taking place June 2-4, 2026 in Boston, Massachusetts. The presentation, titled "Advancing ATH-1105 in ALS: Strategic Trial Design, Biomarker Integration & Adaptive Methodologies," provided an overview of the company's brelgometon (ATH-1105) clinical development program in amyotrophic lateral sclerosis (ALS). Brelgometon is an or
- ANALYSTPiper Sandler initiated coverage on LeonaBio with a new price targetPiper Sandler initiated coverage of LeonaBio with a rating of Overweight and set a new price target of $20.00
- PRLeonaBio to Participate in Upcoming Medical and Industry Meetings in JuneBOTHELL, Wash., May 27, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ:LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced that it will participate in the 5th Annual ALS Drug Development Summit, taking place June 2-4, 2026 in Boston, MA, and the BIO International Convention, taking place June 22-25, 2026 in San Diego, CA. Details are as follows: 5th Annual ALS Drug Development Summit Oral Presentation Title: Advancing ATH-1105 in ALS: Strategic Trial Design, Biomarker Integration & Adaptive MethodologiesSession Title: Redefining Biomarkers and Trial Design to Accelerate Neurodeg
- SECSEC Form DEFA14A filed by LeonaBio Inc.DEFA14A - LeonaBio, Inc. (0001620463) (Filer)
- SECSEC Form DEF 14A filed by LeonaBio Inc.DEF 14A - LeonaBio, Inc. (0001620463) (Filer)
- INSIDERSEC Form 4 filed by Director Holles Natalie C.4 - LeonaBio, Inc. (0001620463) (Issuer)
- INSIDERSEC Form 4 filed by Director Silverman Peter B.4 - LeonaBio, Inc. (0001620463) (Issuer)
- INSIDERSEC Form 4 filed by Director Callori Fred4 - LeonaBio, Inc. (0001620463) (Issuer)
- INSIDERSEC Form 3 filed by new insider Silverman Peter B.3 - LeonaBio, Inc. (0001620463) (Issuer)
- INSIDERSEC Form 3 filed by new insider Holles Natalie C.3 - LeonaBio, Inc. (0001620463) (Issuer)
- INSIDERSEC Form 3 filed by new insider Callori Fred3 - LeonaBio, Inc. (0001620463) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by LeonaBio Inc.SCHEDULE 13D/A - LeonaBio, Inc. (0001620463) (Subject)
- SECSEC Form 10-Q filed by LeonaBio Inc.10-Q - LeonaBio, Inc. (0001620463) (Filer)
- SECLeonaBio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - LeonaBio, Inc. (0001620463) (Filer)
- PRLeonaBio Reports First Quarter 2026 Financial Results and Provides Business UpdateAdvancing Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator, a Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations Expects to Complete Enrollment of Phase 3 Clinical Trial of Lasofoxifene in Treatment-Resistant ER-positive, HER2-negative, ESR1-mutated Metastatic Breast Cancer in 4Q 2026 with Topline Data Anticipated in 2H 2027 On-track to Initiate Phase 2 Proof-of-Concept Study of ATH-1105 in ALS patients in 2H 2026 Recent Events Include Three Appointments to Board of Directors and Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene BOTHELL, Wash., May 07, 2026 (GLOBE NEWSWIRE) -- Leon
- PRLeonaBio Enhances Board of Directors with Appointments of Fred Callori, J.D., Natalie Holles and Peter B. Silverman, J.D.BOTHELL, Wash., May 07, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ:LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced the appointment of Fred Callori, J.D., Natalie Holles, and Peter B. Silverman, J.D. to its Board of Directors, effective as of May 5, 2026. The company also announced that John Fluke, Jr., who has served on the Board of Directors since 2014, retired effective May 4, 2026. "We are delighted to welcome Fred, Natalie, and Peter to LeonaBio's Board of Directors," said Mark Litton, Ph.D., President and Chief Executive Officer of LeonaBio. "Collectively, they bring
- PRLeonaBio to Host Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene in Treatment-Resistant ER+/HER2-, ESR1-Mutated Metastatic Breast CancerManagement to be Joined by Two Clinical Leaders in the Breast Cancer Field Expected to Complete Enrollment in Ongoing ELAINE-3 Phase 3 Registrational Study of Lasofoxifene in Metastatic Breast Cancer in 4Q26 with Data Expected in 2H27 Webinar Event on Wednesday, April 29, 2026, at 12:00 p.m. ET BOTHELL, Wash., April 23, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ:LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced that it will host a virtual Key Opinion Leader event with two leading physician experts in the breast cancer field to discuss the current and evolving treatment la
- PRIndependent Nonclinical Research on Lasofoxifene Presented at American Association for Cancer Research Annual Meeting 2026 Consistent with LeonaBio's DataBOTHELL, Wash., April 21, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ:LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, attended the American Association for Cancer Research Annual Meeting 2026 (AACR26), where independent researchers at Virginia Commonwealth University's Massey Comprehensive Cancer Center presented nonclinical data on lasofoxifene, including its potential for a bone protective role in metastatic breast cancer.1 "We are delighted to learn the findings of this independent research at AACR26, attended by an audience of the world's leading oncology researchers. We believe these
- INSIDERSEC Form 4 filed by Panzara Michael A.4 - LeonaBio, Inc. (0001620463) (Issuer)
- INSIDERSEC Form 4 filed by Church Kevin4 - LeonaBio, Inc. (0001620463) (Issuer)
- INSIDERSEC Form 4 filed by Kosacz Barbara4 - LeonaBio, Inc. (0001620463) (Issuer)
- INSIDERSEC Form 4 filed by Pickering Grant4 - LeonaBio, Inc. (0001620463) (Issuer)
- INSIDERSEC Form 4 filed by Romano Kelly A4 - LeonaBio, Inc. (0001620463) (Issuer)
- INSIDERSEC Form 4 filed by Johnson James A4 - LeonaBio, Inc. (0001620463) (Issuer)
- INSIDERSEC Form 4 filed by Edelman Joseph4 - LeonaBio, Inc. (0001620463) (Issuer)
LONA FAQ
6 questionsWhere does LONA stock trade?
LeonaBio Inc. (LONA) is listed on NASDAQ.What sector and industry is LONA in?
LeonaBio Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did LeonaBio Inc. go public?
LeonaBio Inc. (LONA) completed its IPO in 2020.What are analysts saying about LONA?
LeonaBio Inc. has had 3 recent analyst actions on file. The most recent action was from Piper Sandler: Overweight with a $2000.00 price target on 2026-05-27. Recent price targets range from $1000.00 to $2000.00.What companies are similar to LONA?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare LONA side-by-side with any of them on Quantisnow.How can I track LONA on Quantisnow?
Quantisnow aggregates LeonaBio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LONA to receive live email and push alerts on every new disclosure.